EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients

Yannick Degboé, Maella Severino-Freire, Guillaume Couture, Pol-André Apoil, Nicolas Gaudenzio, Olivier Hermine, Adeline Ruyssen-Witrand, Carle Paul, Michel Laroche, Arnaud Constantin, Cristina Bulai Livideanu

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.02.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Yannick Degboé und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France; INFINITY-Toulouse Institute for Infectious and Infla…. Hauptthemen laut MEDLINE: Osteoporosis, Mastocytosis, Cutaneous, Mastocytosis, Systemic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Systemic mastocytosis (SM) is a clonal disorder of mast cells (MCs) frequently associated with vertebral osteoporosis (OP) and subsequent vertebral fractures (VFs). The natural history of this OP remains unclear. Importantly, we do not know whether OP represents an early event triggered alongside MC abnormalities, and whether MC clonality is sufficient to trigger osteoporosis. OBJECTIVE: To describe OP in patients with medullar clonality in cutaneous mastocytosis (CM) and monoclonal mast cell activation syndrome (MMAS) and to compare their osteoporosis characteristics with those of nonadvanced SM patients (bone marrow mastocytosis and indolent systemic mastocytosis). METHODS: We retrospectively analyzed clinical, biological, and densitometric data of 27 CM, 13 MMAS, and 135 SM patients from the Mastocytosis Expert Center (CEREMAST) in Toulouse, France. RESULTS: The OP (respectively 3.7, 30.8, and 34.1%) and VFs (0.0%, 15.4%, and 20%) were less frequent in CM than in MMAS and SM, despite the presence of clonal MCs in the bone marrow. Most patients with OP and VFs in the non-SM groups had the usual risk factors for OP. Interestingly, the only non-SM patient with a typical SM-like OP had high bone marrow tryptase, developed bone marrow KIT mutation during follow-up, and had a family history of SM. Our data show that OP is not a common clinical finding in CM but is frequent in MMAS. When OP and VFs occur in CM and MMAS patients, they differ from the usual phenotype of SM bone fragility. CONCLUSIONS: Our findings suggest that, in most CM patients, the meaning and management of OP differs from that of OP in MMAS and nonadvanced SM. Prospective longitudinal studies and the validation of predictors are needed to identify CM and MMAS patients developing SM-related OP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisMastocytosis, CutaneousMastocytosis, SystemicHumansFemaleMaleMiddle AgedAdultPrevalenceRetrospective StudiesAgedMast CellsFranceBone MarrowProto-Oncogene Proteins c-kitSpinal Fractures

Stichwörter der Autor:innen

Clonal mast cell disorderFractureOsteoporosisSystemic mastocytosis

Substanzen

Proto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France; INFINITY-Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291- CNRS UMR5051- University Toulouse II…
  • Department of Dermatology and Mastocytosis Expert Centre (CEREMAST), Toulouse University Hospital and University Toulouse III, Toulouse, France.
  • Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France.
  • Department of Dermatology and Mastocytosis Expert Centre (CEREMAST), Toulouse University Hospital and University Toulouse III, Toulouse, France; Department of Immunology, Toulouse University Hospital and University Toul…
  • INFINITY-Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291- CNRS UMR5051- University Toulouse III, Toulouse, France.
  • Department of Hematology and Mastocytosis Expert Centre (CEREMAST), Necker Children's Hospital and Paris Descartes University, Assistance Publique Hôpitaux de Paris, Paris, France.

Zitieren

APA

Degboé, Y., Severino-Freire, M., Couture, G., Apoil, P. A., Gaudenzio, N., Hermine, O., Ruyssen-Witrand, A., Paul, C., Laroche, M., Constantin, A., & Livideanu, C. B. (2024). The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.02.021

Vancouver

Degboé Y, Severino-Freire M, Couture G, Apoil PA, Gaudenzio N, Hermine O, et al. The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.02.021

BibTeX
@article{Degbo2024,
  author = {Degboé, Yannick and Severino-Freire, Maella and Couture, Guillaume and Apoil, Pol-André and Gaudenzio, Nicolas and Hermine, Olivier and Ruyssen-Witrand, Adeline and Paul, Carle and Laroche, Michel and Constantin, Arnaud and Livideanu, Cristina Bulai},
  title = {The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.02.021}
}
Kostenlos starten →